ArticleJMIR formative research2025
Self-Stigma in Adults Living With Chronic Skin Disease: Development of the HautKompass Web-Based Program and Pilot Test of Its Usability, Acceptability, and Feasibility.
Article in JMIR formative research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Self-stigma is common among people with chronic skin disease and can substantially impair quality of life and psychosocial well-being. Few interventions targeting skin disease-related self-stigma are available, especially in Germany. Objective: This pilot study aims to develop a web-based self-guided program to reduce self-stigma among people with chronic skin disease, and test its usability, acceptability, and feasibility. Methods: We developed the HautKompass program based on 2 systematic literature reviews and the expertise from psychodermatologists and patients. Its usability, acceptability, and feasibility were tested among adults with psoriasis, atopic dermatitis, hidradenitis suppurativa, alopecia areata, and vitiligo. After completing the program, participants provided feedback on each session and on their overall experience using the Client Satisfaction Questionnaire and study-specific feedback items. The program was considered feasible if the dropout rate was below 40% and participants spent 45 minutes or less per session. Data were analyzed descriptively. Results: HautKompass is grounded in compassion-focused therapy and cognitive behavioral therapy and consists of 8 self-guided sessions. Of the 41 persons who provided informed consent and filled in the screening questionnaire, 29 were eligible for participation. A total of 27 participants started the program and 20 completed all sessions and the posttest questionnaire. Results indicated high usability (mean 26.12, SD 6.13; on a scale ranging from 8-32) and acceptability (mean 17.41, SD 3.12; on a scale ranging from 5-20). Users rated the program as helpful, the psychoeducation and exercise instructions as comprehensible, and the extent of the program as adequate. Criticism concerned the length of some sessions, the electronic voice used in exercises, and some of the examples being too "general" or "cliché." Regarding feasibility, the program's extent was deemed adequate, participants spent substantially less time on the individual sessions (mean 16.9, SD 4.4 minutes) than the predefined criterion and few participants dropped out after starting the program (n=7, 26%), indicating low barriers. Importantly, the majority of users dropped out within the first 2 sessions, possibly due to the slightly longer duration and focus on theory, or due to unmet expectations, highlighting areas for improvement. Conclusions: Overall, HautKompass was found to be a usable, acceptable program with feasible implementation. Limitations of this pilot study include not testing accessibility for people with disabilities and the small, relatively young, and mostly female sample, which limits the generalizability of the findings. The feedback obtained was used to revise the program and the recruitment strategy prior to testing its effectiveness in a randomized controlled trial. If HautKompass is found to be effective in reducing skin disease-related self-stigma, it will be made widely available to improve psychosocial care for people with chronic skin disease and could be adapted for other skin diseases and visible differences in general.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.